Sacituzumab Tirumotecan Final TNBC Analysis Shows Median OS of 14.7 Months
Start here
At the ESMO congress, Kelun-Biotech presented the final overall survival analysis of its TROP2 antibody-drug conjugate sacituzumab tirumotecan (SKB264) in a China trial of second-line and later advanced triple-negative breast cancer. After 29.4 months of follow-up, patients on the ADC had a median overall survival of 14.7 months versus 9.9 months with chemotherapy, a hazard ratio of 0.60; adjusting for subsequent ADC treatment as a confounder strengthened the effect to HR 0.55. The results add mature survival evidence to the drug's profile in a setting where post-chemotherapy options remain limited. Open questions include how the magnitude of benefit translates outside the trial population and how the agent positions against other ADCs in the same indication.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatPickKelun-Biotech TROP2 ADC Sacituzumab Tirumotecan Posts Final TNBC OS, Median OS 14.7 Months
At the ESMO congress, Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (SKB264) presented the final overall survival analysis of a China trial in second-line and later advanced triple-negative breast cancer. With 29.4 months of follow-up, median OS was 14.7 months versus 9.9 months with chemotherapy, HR=0.60; after adjusting for subsequent ADC treatment as a confounder, HR=0.55.
Coverage and heat for this story
Reports so far 1·Heat now 8·Peak heat 10 (Oct 19 20:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.